Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Taysha Gene Therapies ( (TSHA) ) has shared an announcement.
On November 4, 2025, Taysha Gene Therapies announced amendments to its Sales Agreement, increasing the aggregate offering amount to $212 million, and terminating its agreement with Leerink Partners LLC. The company also reported significant progress in its TSHA-102 program for Rett syndrome, including receiving FDA Breakthrough Therapy designation and finalizing pivotal trial protocols, positioning it to expedite its Biologics License Application submission. Taysha regained full rights to the TSHA-102 program, enhancing its strategic flexibility, and appointed David McNinch as Chief Commercial Officer to strengthen its commercial leadership.
The most recent analyst rating on (TSHA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.
Spark’s Take on TSHA Stock
According to Spark, TipRanks’ AI Analyst, TSHA is a Neutral.
Taysha Gene Therapies’ stock score is primarily influenced by its challenging financial performance, despite strong technical momentum and positive earnings call highlights. The company’s ongoing financial losses and cash flow issues weigh heavily on the score, though clinical progress and regulatory achievements provide a positive outlook.
To see Spark’s full report on TSHA stock, click here.
More about Taysha Gene Therapies
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS).
Average Trading Volume: 6,143,689
Technical Sentiment Signal: Buy
Current Market Cap: $1.22B
Find detailed analytics on TSHA stock on TipRanks’ Stock Analysis page.